NCT00526669 - Study For Patients With Untreated Gastric Cancer Who Will Receive Capecitabine And Lapatinib | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

March 31, 2008

Primary Completion Date

April 30, 2011

Study Completion Date

January 31, 2015

Conditions

Neoplasms, Gastrointestinal Tract

Interventions

DRUG

Lapatinib and Capecitabine

oral lapatinib (1250mg) administered as a monotherapy run-in followed by its combination with capecitabine

Trial Locations (22)

100

GSK Investigational Site, Taipei

104

GSK Investigational Site, Taipei

112

GSK Investigational Site, Taipei

500

GSK Investigational Site, Changhua

20007

GSK Investigational Site, Washington D.C.

48109

GSK Investigational Site, Ann Arbor

48195

GSK Investigational Site, Southgate

65109

GSK Investigational Site, Jefferson City

71103

GSK Investigational Site, Shreveport

75137

GSK Investigational Site, Dallas

90033

GSK Investigational Site, Los Angeles

92354

GSK Investigational Site, Loma Linda

197022

GSK Investigational Site, Saint Petersburg

414044

GSK Investigational Site, Astrakhan

450054

GSK Investigational Site, Ufa

454087

GSK Investigational Site, Chelyabinsk

H3T 1E2

GSK Investigational Site, Montreal

CP 14080

GSK Investigational Site, Mexico City

519-809

GSK Investigational Site, Hwasun

110-744

GSK Investigational Site, Seoul

120-752

GSK Investigational Site, Seoul

442-723

GSK Investigational Site, Suwon, Gyeonggi-do